Showing 4861-4870 of 5623 results for "".
- Samsung Bioepis Announces 24-Week Interim Results From a Phase 3 Trial of Ranibizumab Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-24-week-interim-results-from-a-phase-3-trial-of-ranibizumab-biosimilar/2477785/Samsung Bioepis announced that the primary endpoints have been met in the randomized, double-masked, phase 3 trial comparing the efficacy, safety and immunogenicity of SB11, a ranibizumab biosimilar candidate, to reference ranibizumab in patients with wet age-related macular degeneration (AMD).</
- Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-reports-topline-data-from-phase-2-trial-with-ocs-01-for-treating-inflammation-and-pain-following-cataract-surgery/2477782/Oculis SA reported positive results from its phase 2 SKYGGN study of OCS-01, a novel, high concentration, preservative free, topical SNP formulation of dexamethasone (ophthalmic suspension 1.5%) for the treatment of inflammation and pain following cataract surgery. OCS-01 has been develope
- AMA Issues Guidance to Physicians on Using COVID-19 Antibody Testshttps://modernod.com/news/ama-issues-guidance-to-physicians-on-using-covid-19-antibody-tests/2477783/As new serology tests for COVID-19 rapidly come to the market, the American Medical Association (AMA) is cautioning physicians about using these tests to make healthcare decisions for individual patients, according to a FierceHealthcare
- Prevent Blindness Unveils New Brand Identity, Logo and Websitehttps://modernod.com/news/prevent-blindness-unveils-new-brand-identity-logo-and-website/2477772/Prevent Blindness announced the launch of its new brand identity, logo, and website. The launch coincides with the organization’s new “Be a Visionary” campaign: a call to action to join in the sight-saving efforts of Prevent Blindness. The new identity is designed to refl
- Johnson & Johnson Vision Announces Global Initiatives to Support Eye Care Professionals and Patients During COVID-19 and Beyondhttps://modernod.com/news/johnson-johnson-vision-announces-global-initiatives-to-support-eye-care-professionals-and-patients-during-covid-19-and-beyond/2477770/Johnson & Johnson Vision is deploying solutions around the world to help address the challenges facing eye care professionals (ECPs) and their patients amid the COVID-19 pandemic. These support the broader efforts that Johnson & Johnson is taking to curb the crisis, including development
- Blanchard Contact Lenses Launches Onefit Spotlight Programhttps://modernod.com/news/blanchard-contact-lenses-launches-onefit-spotlight-program/2477769/Blanchard Contact Lenses has announced the launch of their new Onefit Spotlight program, which was designed to highlight the great work of those who are fitting the Onefit family of scleral lenses. Prac
- Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI For Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-1-clinical-trial-of-otx-csi-for-treatment-of-dry-eye-disease/2477754/Ocular Therapeutix announced that it has dosed the first patients in its phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” Michael Goldst
- Regeneron CEO: Manufacturing Not Up to Snuff for COVID-19 Vaccines, Therapieshttps://modernod.com/news/regeneron-ceo-manufacturing-not-up-to-snuff-for-covid-19-vaccines-therapies/2477753/Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can’t produce a therapy or vaccine fast enough—and the company’s helmsman i
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- Stoke Therapeutics Presents Preclinical Data on Potential Treatment For Inherited Optic Nerve Disorderhttps://modernod.com/news/stoke-therapeutics-presents-preclinical-data-on-potential-treatment-for-inherited-optic-nerve-disorder/2477751/Stoke Therapeutics announced new preclinical data demonstrating in-vitro and in-vivo target engagement and protein upregulation in OPA1 protein-deficient cells. OPA1 protein deficiency is the primary cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorde